Not Yet RecruitingPhase 3ACTRN12605000029695

Tenofovir versus Adefovir for the treatment of HBeAg negative chronic hepatitis B

A randomised, phase III, double blind study to evaluate the efficacy and safety of tenofovir DF versus adefovir dipivoxil in the treatment of presumed pre-core mutant chronic hepatitis B to suppress viral replication, amend the course of the disease and decrease morbidity.

Sponsor

Gilead Sciences Inc

Enrollment

300 participants

Start Date

Aug 1, 2005

Study Type

Interventional

Conditions

HBeAg negative Chronic Hepatitis B

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 69 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares tenofovir to adefovir for treating HBeAg-negative chronic hepatitis B. It is for adults aged 18 to 69 who have chronic hepatitis B with active viral replication but are HBeAg negative. Participation involves daily antiviral medication, regular blood tests, and possible liver biopsies.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

To compare the efficacy of tenofovir DF 300 mg versus adefovir dipivoxil 10mg for the treatment of presumed pre-core mutany chronic hepatitis B over 48 weeks of treatment

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000029695